The “exit” is the holy grail for any startup, especially for a biotechnology company.

Millions of dollars and years of time go into the development of a new therapeutic. If it works, a pharmaceutical company will take a new drug to market; if not, the time and money spent in development and testing will be lost.

For early stage biotechnology investors like i2E, it is a very long game.

Read the rest of the story at oklahoman.com.